Publications by authors named "Sam Keeping"

Claim this Profile
A
Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials.
Scott M Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping

Ophthalmol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis to Investigate the Correlation Between Event-Free Survival and Overall Survival in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma.
Dandan Zheng, Ali Mojebi, Yuexin Tang, Braden Hale, Sanjay Merchant, Sam Keeping

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison.
Marcin Dzienis, Ali Mojebi, Sam Keeping, Christopher M Black, Hilde Giezek

Adv Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.
Benjamin Derman, Carlyn Tan, Ian Steinfield, Florence R Wilson, Dee Lin, Sam Keeping

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.
Catherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad, Kaijun Wang, Ina Zhang, Sam Keeping

Leuk Lymphoma· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
Monique C Minnema, Xiang Yin, Ruthanna Davi, Sam Keeping, Julie E Park

Leuk Lymphoma· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of rapid molecular diagnostic tests in patients presenting with viral respiratory symptoms: A systematic literature review.
Ali Mojebi, Ping Wu, Sam Keeping, Braden Hale, Jordan G Chase

PLoS One· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Gilles Salles, Jenny M H Chen, Ina Zhang, Fabio Kerbauy, James J Wu, Sam Keeping

Adv Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Sam Keeping

Leuk Lymphoma· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients.
Bijal Shah, Jenny M H Chen, James J Wu, Chaoling Feng, Lang Zhou, Sam Keeping

Adv Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Sam Keeping

Br J Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Josephine Louella Feliciano, Dylan McLoone, Yingxin Xu, Ruben G W Quek, Andreas Kuznik, Sam Keeping

Front Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
Olalekan O Oluwole, Jenny M H Chen, Keith Chan, Anik R Patel, Jeroen P Jansen, Sam Keeping

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC.
He Jin, Mayur Amonkar, Raquel Aguiar-Ibáñez, Manasi Thosar, Monica Chase, Sam Keeping

Future Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Nick Freemantle, Yingxin Xu, Florence R Wilson, Patricia Guyot, Chieh-I Chen, Sam Keeping

Ther Adv Med Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.
Christopher M Black, Sam Keeping, Ali Mojebi, Karthik Ramakrishnan, Diana Chirovsky

Front Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Andreas Kuznik, Caitlin Smare, Chieh-I Chen, Meena Venkatachalam, Sam Keeping

Value Health· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Eleanor Paul, Gerasimos Konidaris, Shannon Cope, Chieh-I Chen, Sam Keeping

J Manag Care Spec Pharm· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Vipul Jairath, Keith Chan, Karen Lasch, Sam Keeping, Christian Agboton

Expert Rev Gastroenterol Hepatol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Gerasimos Konidaris, Eleanor Paul, Andreas Kuznik, Sam Keeping, Chieh-I Chen

Value Health· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Sam Keeping, Yingxin Xu, Chieh-I Chen, Shannon Cope, Ali Mojebi

Future Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
Olalekan O Oluwole, Jeroen P Jansen, Vincent W Lin, Keith Chan, Sam Keeping

Biol Blood Marrow Transplant· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer.
Sam T Keeping, Shannon Cope, Keith Chan, Florence R Wilson, Jeroen P Jansen

J Comp Eff Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
Olalekan O Oluwole, Jeroen P Jansen, Vincent W Lin, Keith Chan, Sam Keeping

Biol Blood Marrow Transplant· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
Shannon Cope, Sam T Keeping, Rachel Goldgrub, Dieter Ayers, Jeroen P Jansen

J Comp Eff Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis